Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Papillary renal cell carcinoma, sporadic × GSK 1363089 × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Papillary renal cell carcinoma, sporadic 1 Carcinoma, Renal Cell 1

Interventions

atezolizumab 1 Specimen Handling 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 GSK 1363089 1 Erlotinib Hydrochloride 1 Disulfides 1 Contrast Media 1 Biopsy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00726323 2017-12-11

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

GlaxoSmithKline

Phase 2 Completed

74 enrolled 14 charts

Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡